Purpose
Despite the successful use of tyrosine kinase inhibitors (TKIs) in cancer patients, their effect on herpes zoster development has not been studied. The aim of this study was to evaluate and compare the effects of epidermal growth factor receptor (EGFR) TKI and cytotoxic chemotherapy on the risk of herpes zoster development in non-small cell lung cancer (NSCLC) patients.
Materials and Methods
We conducted a medical review of all eligible NSCLC patients in Seoul National University hospital between 2002 and 2015. We classified patients based on whether they previously underwent EGFR TKI therapy into either the TKI group or the cytotoxic group. We compared the incidence rates of herpes zoster during TKI therapy and cytotoxic chemotherapy. Additionally, the longitudinal risk of herpes zoster from TKIs was analyzed using the incidence rate ratio (IRR) of the TKI group to the cytotoxic group and the log-rank test of the Kaplan-Meier method.
Results
Of the 2,981 NSCLC patients, 54 patients (1.54%) developed herpes zoster. In the TKI group (2,002 patients), the IRR of herpes zoster during TKI therapy compared to that during cytotoxic chemotherapy was 1.05 (95% confidence interval [CI], 0.53 to 2.09). The IRR of the TKI group compared to the cytotoxic group was 1.33 (95% CI, 0.64 to 2.76). The Kaplan-Meier cumulative risk of both groups was not significantly different.
Conclusion
Our results show that the incidence rate of herpes zoster in the TKI group was not statistically different from the incidence in the cytotoxic group during and after chemotherapy in NSCLC patients.
Citations
Citations to this article as recorded by
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects Bei Cao, Tingting Ma, Yuqiang Zhang, Lei Huang, Hui Lin, Huanhuan Jiang, Yu Zhao, Yan Geng, Yuanxun Yang, Sumin Cao, Juan Li Investigational New Drugs.2024; 42(3): 289. CrossRef
Reactivation of Varicella-Zoster Virus in Patients with Lung Cancer Receiving Immune Checkpoint Inhibitors: Retrospective Nationwide Population-Based Cohort Study from South Korea Jiyun Jung, Seong-Yeon Park, Jae-Yoon Park, Dalyong Kim, Kyoungmin Lee, Sungim Choi Cancers.2024; 16(8): 1499. CrossRef
Generalized herpes zoster and cutaneous metastasis during chemotherapy for non‐small cell lung cancer: A case report Naoya Yasokawa, Yuri Yasuda, Houhi Chin, Koji Kurose, Yumi Aoyama, Toru Oga Thoracic Cancer.2021; 12(1): 117. CrossRef
The risk of herpes zoster among patients with ankylosing spondylitis: A population‐based cohort study in Taiwan Shuya Wang, James Cheng‐Chung Wei, Jing‐Yang Huang, Wuu‐Tsun Perng, Zhiyi Zhang International Journal of Rheumatic Diseases.2020; 23(2): 181. CrossRef
Jaewon Lee, Jin Lim, Jong Seo Park, Miso Kim, Tae-Yong Kim, Tae Min Kim, Kyung-Hun Lee, Bhumsuk Keam, Sae-Won Han, Je-Ho Mun, Kwang Hyun Cho, Seong Jin Jo
Cancer Res Treat. 2018;50(4):1186-1193. Published online December 14, 2017
Purpose
Patients treated with anticancer agents often experience a variety of treatment-related skin problems, which can impair their quality of life.
Materials and Methods
In this cross-sectional study, Dermatology Life Quality Index (DLQI) and clinical information were evaluated in patients under active anticancer treatment using a questionnaire survey and their medical records review.
Results
Of 375 evaluated subjects with anticancer therapy, 136 (36.27%) and 114 (30.40%) were treated for breast cancer and colorectal cancer, respectively. We found that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific quality of life distraction. In addition, itching, dry skin, easy bruising, pigmentation, papulopustules on face, periungual inflammation, nail changes, and palmoplantar lesions were associated with significantly higher DLQI scores. Periungual inflammation and palmoplantar lesions scored the highest DLQI.
Conclusion
We believe our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.
Citations
Citations to this article as recorded by
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature Annika Belzer, Jolanta J. Pach, Kailyn Valido, Jonathan S. Leventhal American Journal of Clinical Dermatology.2024; 25(3): 435. CrossRef
Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy Maria Mannino, Pietro Sollena, Alessandro Di Stefani, Ernesto Rossi, Ettore D’Argento, Giovanni Schinzari, Giampaolo Tortora, Ketty Peris Dermatology.2024; 240(4): 523. CrossRef
A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country Areesha Abid, Humza Saeed, Uswa Iftikhar, Muhammad Khubaib Arshad, Muhammad Uzair Shahid, Tayyab Rasool, Faizan Fazal, Aman Goyal, Anum Akbar Journal of Oncology Pharmacy Practice.2024;[Epub] CrossRef
Chemotherapy induced alopecia in breast cancer patients: A monocentric prospective study Wala Ben Kridis, Olfa Boudawara, Afef Khanfir Breast Disease.2024; 43(1): 251. CrossRef
Impact of Xerosis in Patients With Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional, Prospective, Pilot Study Pietro Quaglino, Giuseppe Argenziano, Emi Dika, Michela Starace, Simone Amabile, Paolo Fava, Elvira Moscarella, Bianca Maria Piraccini, Alain Delarue, Olivia Dialla, Fabienne Zumaglini, Giampiero Girolomoni Dermatology Practical & Conceptual.2024; 14(4): e2024259. CrossRef
Global trends in adolescent and young adult female cancer burden, 1990-2021: insights from the Global Burden of Disease study Z. Huang, J. Wang, H. Liu, B. Wang, M. Qi, Z. Lyu, H. Liu ESMO Open.2024; 9(11): 103958. CrossRef
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer Maham Ahmad, Sabrina Saeed, Brianna Olamiju, Andrea Silber, Jonathan Leventhal International Journal of Women’s Dermatology.2023; 9(1): e073. CrossRef
Aloe vera gel for prevention of chemotherapy-induced hyperpigmentation: Four case reports Chia-Chi Chiu, Yi-Wen Hsiao, Yu-Chuan Wen, Tsung-Yen Chang, Shih-Hsiang Chen, Tang-Her Jaing Medicine.2023; 102(25): e34037. CrossRef
Skin-related Quality of Life in Patients with Lung Cancer Taking Oral Targeted Agents: A Single-Center, Cross-Sectional Study Joo Mi Park, Jeong Hye Kim Asian Oncology Nursing.2023; 23(2): 84. CrossRef
Dermatological Side Effects of Cancer Treatment: Psychosocial Implications—A Systematic Review of the Literature Vera Almeida, Daniela Pires, Marta Silva, Maribel Teixeira, Ricardo João Teixeira, André Louro, Maria Alzira Pimenta Dinis, Maria Ferreira, Ana Teixeira Healthcare.2023; 11(19): 2621. CrossRef
The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus Brigitte Dreno, Kiarash Khosrotehrani, Giselle De Barros Silva, Julie Ryan Wolf, Delphine Kerob, Mark Trombetta, Etienne Atenguena, Pascale Dielenseger, Meng Pan, Florian Scotte, Ivan Krakowski, Mario Lacouture Supportive Care in Cancer.2023;[Epub] CrossRef
Effectiveness and Tolerability of Natural Herbal Formulations in the Prevention of Radiation-Induced Skin Toxicity in Patients Undergoing Radiotherapy Georgios Koukourakis, Georgios Pissakas, Christos G. Ganos, Gregory Sivolapenko, Dimitrios Kardamakis The International Journal of Lower Extremity Wounds.2022; 21(1): 75. CrossRef
Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes Jang‐Hee Oh, Woojune Hur, Na Li, Seong Jin Jo Experimental Dermatology.2022; 31(6): 918. CrossRef
An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study Véronique Vendrely, Ander Mayor-Ibarguren, Aline Stennevin, Ariadna Ortiz-Brugués Dermatology and Therapy.2022; 12(3): 683. CrossRef
Nail pigmentation induced by chemotherapy: an observational study of patients with early-stage breast cancer Kuikui Jiang, Simei Shi, Qiulian Lin, Peng Sun, Luan Zhang, Zhongyu Yuan, Ruoxi Hong, Yanxia Shi, Xia Liu, Jingmin Zhang, Jiajia Huang, Xiwen Bi, Wen Xia, Qianyi Lu, Qiufan Zheng, Shusen Wang, Fei Xu Holistic Integrative Oncology.2022;[Epub] CrossRef
Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new Hae‐Jin Suh, Ángeles Flórez, Víctor Sacristán, Ángeles Rodríguez Martinez, Francisca Fernández, Lucía Vilanova‐Trillo, Manuel Constenla, Manuel Pereiro International Journal of Dermatology.2021; 60(2): 208. CrossRef
The Impact of Acne, Atopic Dermatitis, Skin Toxicities and Scars on Quality of Life and the Importance of a Holistic Treatment Approach Brigitte Dreno, Jean Michel Amici, Ann Laure Demessant-Flavigny, Charlotte Wright, Charles Taieb, Seemal R Desai, Andrew Alexis Clinical, Cosmetic and Investigational Dermatology.2021; Volume 14: 623. CrossRef
Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study Hae-Jin Suh Oh, Ángeles Flórez Menéndez, Víctor Sacristán Santos, Ángeles Rodríguez Martínez, Francisca Fernández Ribeiro, Lucía Vilanova-Trillo, Manuel Constenla Figueiras, Manuel Pereiro Ferreiros Health and Quality of Life Outcomes.2021;[Epub] CrossRef
Dermatologic conditions in women receiving systemic cancer therapy Michelle N. Ferreira, Julie Y. Ramseier, Jonathan S. Leventhal International Journal of Women's Dermatology.2019; 5(5): 285. CrossRef